Login to Your Account



Financings NEWS
Zafgen Inc.'s shares (NASDAQ:ZFGN) rose 5 percent to $38.97 Friday as the company priced a public offering of about 3.9 million shares at $35 each.
Promising multiple readouts on its HER2-focused experimental cancer therapy neratinib (PB272) in the year ahead, Puma Biotechnology Inc. unleashed plans for a $190 million follow-on offering to back clinical work and a planned first quarter 2016 new drug application (NDA) for the tyrosine kinase inhibitor.
HONG KONG – A Chinese biopharmaceutical company with a newly built facility in Suzhou Industrial Park has completed a series C financing of almost $100 million. The funds will help the company develop and manufacture complex and high-end biologics, including biosimilars.
More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: